---
title: "WuXi AppTec Co., Ltd. (603259.SH) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603259.SH/overview.md"
symbol: "603259.SH"
name: "WuXi AppTec Co., Ltd."
parent: "https://longbridge.com/en/quote/603259.SH.md"
datetime: "2026-04-04T14:31:36.634Z"
locales:
  - [en](https://longbridge.com/en/quote/603259.SH/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603259.SH/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603259.SH/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/603259.SH/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/603259.SH/overview.md)


# WuXi AppTec Co., Ltd. (603259.SH) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Address | No.5 Mashan Bridge, Binhu District, Wuxi City, Jiangsu Province |
| Website | [www.wuxiapptec.com.cn](https://www.wuxiapptec.com.cn) |

## Company Profile

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization.

## Key Executives

| Name | Title |
|------|-------|
| Ge Li(李革) | 董事长 & 总裁 & 首席执行官(CEO) |
| 韩敏 | 董事会秘书 & 公司秘书 & 授权代表 |
| 张朝晖 | 副总裁 |
| 施明 | 首席财务官 |
| Minzhang Chen(陈民章) | 联席首席执行官 |
| Steve Qing Yang(杨青) | 联席首席执行官 |
| 张远舟 | 环境、社会及管治委员会委员 |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| 香港中央结算(代理人)有限公司 | 17.11% | 2026-03-24 |
| 香港中央结算有限公司 | 6.58% | 2026-03-24 |
| G&C VI Limited | 4.36% | 2026-03-24 |
| G&C IV Hong Kong Limited | 3.19% | 2026-03-24 |
| 北京中民银孚投资管理有限公司-嘉兴宇祥投资合伙企业(有限合伙) | 2.65% | 2026-03-24 |
| G&C V Limited | 2.23% | 2026-03-24 |
| 中国工商银行-上证50交易型开放式指数证券投资基金 | 1.53% | 2026-03-24 |
| 中国工商银行股份有限公司-华泰柏瑞沪深300交易型开放式指数证券投资基金 | 1.37% | 2026-03-24 |
| G&C VII Limited | 1.15% | 2026-03-24 |
| 中国建设银行股份有限公司-易方达沪深300医药卫生交易型开放式指数证券投资基金 | 1.10% | 2026-03-24 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Chemical Business | 36465846882 | 80.22% |
| Test Business | 4041701030 | 8.89% |
| Biology Business | 2677175030 | 5.89% |
| Discontinued Operations | 2035342035 | 4.48% |
| Others | 236100794 | 0.52% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "WuXi AppTec Co., Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Chemical Business",
        "ratio": 80.22
      },
      {
        "segment": "Test Business",
        "ratio": 8.89
      },
      {
        "segment": "Biology Business",
        "ratio": 5.89
      },
      {
        "segment": "Discontinued Operations",
        "ratio": 4.48
      },
      {
        "segment": "Others",
        "ratio": 0.52
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| Overseas | 37954185900 | 83.5% |
| China | 5466637900 | 12.03% |
| Discontinued Operations | 2035342000 | 4.48% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**